ATE455174T1 - Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein - Google Patents

Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein

Info

Publication number
ATE455174T1
ATE455174T1 AT07109353T AT07109353T ATE455174T1 AT E455174 T1 ATE455174 T1 AT E455174T1 AT 07109353 T AT07109353 T AT 07109353T AT 07109353 T AT07109353 T AT 07109353T AT E455174 T1 ATE455174 T1 AT E455174T1
Authority
AT
Austria
Prior art keywords
vitamin
dependent protein
coexpress
reductase
productivity
Prior art date
Application number
AT07109353T
Other languages
English (en)
Inventor
Darrel Stafford
Tao Li
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34393028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE455174(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE455174T1 publication Critical patent/ATE455174T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT07109353T 2003-09-23 2004-09-23 Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein ATE455174T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50552703P 2003-09-23 2003-09-23

Publications (1)

Publication Number Publication Date
ATE455174T1 true ATE455174T1 (de) 2010-01-15

Family

ID=34393028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07109353T ATE455174T1 (de) 2003-09-23 2004-09-23 Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein

Country Status (13)

Country Link
US (6) US7687233B2 (de)
EP (4) EP1842920B2 (de)
JP (4) JP2007506433A (de)
AT (1) ATE455174T1 (de)
AU (2) AU2004275828B2 (de)
CA (1) CA2539434C (de)
DE (1) DE602004025157D1 (de)
DK (2) DK2380985T3 (de)
ES (2) ES2453895T3 (de)
HK (1) HK1093223A1 (de)
PL (1) PL1842920T5 (de)
PT (1) PT2380985E (de)
WO (1) WO2005030039A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ES2344413T3 (es) * 2003-10-14 2010-08-26 Baxter International Inc. Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
EP1781779A2 (de) * 2004-08-02 2007-05-09 Novozymes A/S Erzeugung von diversität in polypeptiden
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
EP1809767B1 (de) * 2004-10-18 2011-09-07 University of Washington Verfahren und zusammensetzungen zur vorhersage der reaktion auf warfarin
EP1831402B1 (de) * 2004-12-21 2010-06-09 Academia Sinica Warfarinsensibilität vorhersagende genetische varianten von vkorc1
EP2295547B1 (de) * 2005-02-28 2017-09-20 Baxalta GmbH Rekombinante co-Expression der Vitamin-K-Epoxide-Reduktase-Untereinheit 1 zur Verbesserung der Expression Vitamin-K-abhängiger Proteine
US20090325226A1 (en) * 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
MX2007012704A (es) 2005-04-13 2008-01-14 Astrazeneca Ab Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
US8500720B2 (en) * 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
WO2007075976A2 (en) * 2005-12-21 2007-07-05 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin k dependent proteins by recombinant methods
US20070298426A1 (en) * 2006-06-02 2007-12-27 Academia Sinica Warfarin dosage prediction
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
UA101497C2 (ru) 2008-04-24 2013-04-10 Селтик Фарма Пег Лтд. Конъюгаты фактора ix с увеличенным временем полужизни
US20110243958A1 (en) * 2008-10-15 2011-10-06 President And Fellows Of Harvard College Antimicrobial agents that target bacterial vkor
WO2011003153A1 (en) 2009-07-10 2011-01-13 Csl Limited Method of increasing the expression yield of vitamin k-dependent proteins
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
JP2012139232A (ja) * 2012-03-15 2012-07-26 Univ Of North Carolina At Chapel Hill 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
JP2014221048A (ja) * 2014-06-16 2014-11-27 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
BR102015012334A2 (pt) * 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
EP4252629A3 (de) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0127839B1 (de) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Verfahren zur Herstellung eines rekombinanten Baculovirus-Expressionsvektors
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
AU5864086A (en) 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0289586A4 (de) 1986-11-17 1990-04-10 New England Medical Ct Steigerung der gamma-carboxylation von rekombinanten, vitamin-k-abhängigen proteinen.
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
WO1991001372A1 (en) 1989-07-17 1991-02-07 New England Medical Center Hospitals, Inc. VITAMIN K-DEPENDENT η-CARBOXYLASE
JPH05508551A (ja) * 1990-07-23 1993-12-02 ザイモジェネティクス，インコーポレイティド ガンマーカルボキシラーゼおよび使用の方法
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
DK0574402T3 (da) 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5698765A (en) * 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) * 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) * 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) * 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−１遺伝子の機能が欠損したマウス
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5547835A (en) * 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
GB2303853B (en) 1994-06-16 1998-12-23 Us Health Variant alleles in cytochrome P450 expressing enzymes involved in metabolic processes
ZA965853B (en) * 1995-07-13 1998-01-12 Du Pont Merck Pharma Asymmetric synthesis of r and s warfarin and its analogs.
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
WO2002102994A2 (en) * 2001-03-21 2002-12-27 Human Genome Sciences, Inc. Human secreted proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
EP1042473A1 (de) * 1997-12-24 2000-10-11 Immunex Corporation V201 dna und polypeptide
US5896337A (en) 1998-02-23 1999-04-20 Micron Technology, Inc. Circuits and methods for multi-level data through a single input/ouput pin
WO2000003015A2 (en) * 1998-07-10 2000-01-20 Incyte Pharmaceuticals, Inc. Human transport protein homologs
CN1289448A (zh) * 1998-11-18 2001-03-28 皇家菲利浦电子有限公司 荧光材料
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
KR100880624B1 (ko) 2000-10-02 2009-01-30 노보 노르디스크 헬스 케어 악티엔게젤샤프트 비타민 ｋ-의존 단백질의 생산 방법
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ES2344413T3 (es) 2003-10-14 2010-08-26 Baxter International Inc. Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
EP1809767B1 (de) 2004-10-18 2011-09-07 University of Washington Verfahren und zusammensetzungen zur vorhersage der reaktion auf warfarin
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006067116A1 (en) 2004-12-21 2006-06-29 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
EP1831402B1 (de) * 2004-12-21 2010-06-09 Academia Sinica Warfarinsensibilität vorhersagende genetische varianten von vkorc1
EP2295547B1 (de) 2005-02-28 2017-09-20 Baxalta GmbH Rekombinante co-Expression der Vitamin-K-Epoxide-Reduktase-Untereinheit 1 zur Verbesserung der Expression Vitamin-K-abhängiger Proteine
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
MX2007012704A (es) 2005-04-13 2008-01-14 Astrazeneca Ab Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
ATE486128T1 (de) 2005-12-02 2010-11-15 Univ Wake Forest Health Sciences Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
WO2007075976A2 (en) 2005-12-21 2007-07-05 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin k dependent proteins by recombinant methods
US20070298426A1 (en) 2006-06-02 2007-12-27 Academia Sinica Warfarin dosage prediction
JP2009005240A (ja) * 2007-06-25 2009-01-08 Nec Tokin Corp 無線ネットワークシステムおよび無線ネットワーク通信方法

Also Published As

Publication number Publication date
JP2010268803A (ja) 2010-12-02
AU2004275828B2 (en) 2010-04-29
ES2453895T3 (es) 2014-04-08
EP1842920A1 (de) 2007-10-10
AU2010203318A1 (en) 2010-08-12
ES2339710T5 (es) 2017-10-05
US20110124000A1 (en) 2011-05-26
US7524665B2 (en) 2009-04-28
US20060240440A1 (en) 2006-10-26
US20090215045A1 (en) 2009-08-27
US7482141B2 (en) 2009-01-27
EP1670947A2 (de) 2006-06-21
EP2380985B1 (de) 2014-01-01
EP1670947B1 (de) 2015-04-01
US7858318B2 (en) 2010-12-28
JP2007506433A (ja) 2007-03-22
PL1842920T3 (pl) 2010-06-30
AU2010203318B2 (en) 2012-07-12
JP2012161315A (ja) 2012-08-30
EP1842920B2 (de) 2017-06-21
EP1670947A4 (de) 2008-11-05
US8426128B2 (en) 2013-04-23
ES2339710T3 (es) 2010-05-24
CA2539434C (en) 2014-03-18
US7687233B2 (en) 2010-03-30
PL1842920T5 (pl) 2018-04-30
EP2336360A1 (de) 2011-06-22
DK1842920T3 (da) 2010-05-03
US20070009950A1 (en) 2007-01-11
DK1842920T4 (da) 2017-08-21
DK2380985T3 (en) 2014-03-17
US20090215061A1 (en) 2009-08-27
WO2005030039A3 (en) 2005-07-21
HK1093223A1 (en) 2007-02-23
EP2380985A1 (de) 2011-10-26
US8097410B2 (en) 2012-01-17
US20070190614A1 (en) 2007-08-16
EP1842920B1 (de) 2010-01-13
DE602004025157D1 (de) 2010-03-04
PT2380985E (pt) 2014-03-26
JP5840539B2 (ja) 2016-01-06
JP2015180205A (ja) 2015-10-15
AU2004275828A1 (en) 2005-04-07
CA2539434A1 (en) 2005-04-07
WO2005030039A2 (en) 2005-04-07
JP5094920B2 (ja) 2012-12-12

Similar Documents

Publication Publication Date Title
ATE455174T1 (de) Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein
IL172506A0 (en) New biological entities and the use thereof
AU2003241311A1 (en) Simple catalytic dna biosensors for ions based on color changes
WO2007065025A3 (en) Method of dna analysis using micro/nanochannel
WO2005083127A3 (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
EP2386657A3 (de) Mit Herzkreislauf-Störungen und Medikamentenansprache assoziierte genetische Polymorphien, Detektionsverfahren und Verwendungen davon
ATE389032T1 (de) Methode zur anwendung molekulare konstrukte zur detektion biochemischer reaktionen
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
WO2004058990A3 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
DE60318642D1 (de) Multi-Test-Analyse von Echzeit-Nukleinsäureamplifikationen
WO2007059514A8 (en) Sers-based methods for detection of bioagents
WO2005116257A3 (en) Unique short tandem repeats and methods of their use
WO2007021756A3 (en) Methods for characterizing biological molecule modulators
EP1900822A4 (de) Verfahren zur gleichzeitigen analyse mehrerer biologischer reaktionen oder veränderungen unter in-vivo-bedingungen
ATE405546T1 (de) Verfahren zur oxidation von cyclohexan
WO2006099365A3 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
DE50211356D1 (de) Hybridverfahren zur herstellung von trägern für die analytbestimmung
EP2392667A3 (de) Assay für Phosphodiesterasen
AU2004241519B2 (en) Polymeric microarray support, method of forming microfeatures and on optical assay arrangement
DE60324819D1 (de) Verfahren zur amplifikation von nukleinsäure, kit zur amplifikation von nukleinsäure, verfahren zum nachweis von einzelnukleotid-polymorphismus und reagentienkit zum nachweis von einzelnukleotid-polymorphismus
WO2003098187A3 (en) Assays and kits for detecting the presence of nitriles and/or cyanide
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity
DE60127901D1 (de) TCF-1 Nukleotidsequenzvariation
WO2004101746A3 (en) Production of carotenoids in microorganisms

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties